



QUEST FOR GROWTH

Pricaf, société d'investissement à capital fixe de droit belge

Louvain, le 4 mai 2015

Agilent Technologies s'engage à acquérir Cartagenia

Agilent Technologies Inc. a annoncé ce matin son intention d'acquérir 100 % des actions de Cartagenia. La conclusion finale de la transaction est prévue pour la mi-mai. Cartagenia, une émanation de la KULeuven, fournit des logiciels de diagnostic, des systèmes de bases de données et services apparentés aux laboratoires et cliniciens génétiques pour leur permettre d'exécuter rapidement et efficacement les analyses génétiques pertinentes et d'offrir aux patients et soignants une interprétation génétique et un encadrement de qualité. Agilent (NYSE : A) est un leader mondial dans le domaine des sciences de la vie, du diagnostic et de la chimie appliquée.

Quest for Growth investit indirectement dans Cartagenia par le biais de sa participation dans Capricorn ICT Arkiv. En cas de conclusion fructueuse, Quest for Growth prévoit que la transaction aura sur sa valeur nette d'inventaire un impact positif d'environ 3 %.

Pour toute information complémentaire, veuillez consulter le communiqué de presse d'Agilent joint.

À propos de Quest for Growth

QUEST FOR GROWTH est une Pricaf, soit un Organisme de Placement Collectif à capital fixe de droit belge. Le portefeuille diversifié de Quest for Growth est investi essentiellement dans des entreprises en croissance cotées sur des bourses européennes, dans des entreprises non cotées européennes et dans des fonds de capital-risque. Quest for Growth se concentre sur des entreprises innovantes dans des domaines tels que les technologies de l'information et de la communication (ICT), les technologies relatives aux soins de santé (Health-tech) et les technologies propres (Cleantech). Quest for Growth est cotée sur Euronext Bruxelles depuis le 23 septembre 1998.

www.questforgrowth.com

Pour toute information complémentaire :

Capricorn Venture Partners SA,
gestionnaire de Quest for Growth,
Dr. Jos B. Peeters, Managing Partner
Tél: +32 (0)16 28 41 00

Ce communiqué n'est pas une offre de vente ni un appel d'offre d'achat de titres des sociétés citées, et dans lesquelles QUEST FOR GROWTH a investi. Il n'est fait qu'à titre purement informatif. Le présent communiqué de presse peut faire état de perspectives impliquant une part de risque et d'incertitude. Bien que QUEST FOR GROWTH estime que les expectations contenues dans de tels états sont basées sur des présomptions raisonnables, aucune garantie ne peut être donnée que de telles projections vont effectivement se réaliser. Toutes ces prévisions doivent être considérées tout en sachant que les événements et résultats réels peuvent différer de ces prédictions eu égard à des éléments tels que des modifications politiques, économiques ou juridiques sur les marchés où sont actives les sociétés dans lesquelles QUEST FOR GROWTH investit ou sur les Bourses où sont cotées ces sociétés. Les lecteurs se référeront au prospectus émis lors de l'introduction en Bourse de QUEST FOR GROWTH et qui identifie les facteurs de risque importants propres à la société.



QUEST FOR GROWTH SA
Pricaf, société d'investissement à capital fixe de droit belge
Lei 19 - bte 3, B-3000 Louvain - Tél: +32 (0)16 28 41 00 - Fax: +32 (0)16 28 41 08

www.questforgrowth.com
quest@questforgrowth.com

Agilent Technologies to Acquire Cartagenia, Leading Provider of Software to Enable Clinical Analysis of Genomics Data

SANTA CLARA, Calif., and BOSTON, May 4, 2015 – Agilent Technologies Inc. (NYSE: A) and Cartagenia today announced that they have signed a definitive agreement under which Agilent will acquire Cartagenia, a leading provider of software and services for clinical genetics and molecular pathology labs.

Cartagenia, which has offices in Leuven, Belgium, and Boston, Massachusetts, provides software solutions for variant assessment and reporting of clinical genomics data from next-generation sequencing and microarrays. Uniquely geared to routine clinical labs, Cartagenia's solutions are FDA-registered as exempt Class I Medical Devices in the U.S. and as Class I Medical Devices in Europe. The Cartagenia Bench platform enables technicians, lab directors and clinicians to visualize, assess and report clinical genetics data in the context of patient information.

With Cartagenia Bench, labs can build an internal knowledge base, build variant assessment SOPs, automate report drafting, and access a wide range of community-validated, private and premium content resources, whether for oncology or inherited disease.

Cartagenia's platform also provides deep support for consortia of collaborating labs. Data-sharing has become an essential requirement for the community, and through private and public consortia, users can connect and pool their knowledge on rare diseases and actionable findings.

"Cartagenia's approach to enabling the interpretation of clinical genomics data is revolutionary," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group. "We look forward to providing Cartagenia's software solutions to our clinical genetics and molecular oncology customers and to providing Cartagenia's existing customers with access to our global service and support network. Together, Agilent and Cartagenia can help remove bottlenecks inherent in analysis, interpretation and reporting clinical data—resulting in faster answers for patients."

“Joining forces with Agilent is an excellent strategic fit and provides tremendous opportunity both for our customers—who will benefit from integration with a broad family of solutions and a range of new applications—and for our team, as we’ll be able to further accelerate our success and growth through Agilent’s global reach and leading footprint in clinical labs,” said Herman Verrelst, chief executive officer, Cartagenia.

The acquisition is expected to be completed May 19, subject to local laws and regulations and customary closing conditions. Cartagenia employs 36 people, all of whom will be offered employment with Agilent.

Financial terms of the transaction were not disclosed.

About Cartagenia

Cartagenia supplies variant assessment support and lab report automation software, database systems, and related services to genetic labs, pathology labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high-quality genetic interpretation and counseling.

Cartagenia Bench Lab allows automation of variant assessment protocols and lab report generation for structural and molecular variant assays such as Arrays, Sanger and Next Generation Sequencing. It supports communication with referring physicians, allows labs and clinicians to put variants in their clinical context, and supports confident data sharing.

The Cartagenia Bench platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab addresses the specific needs of genetic diagnostic labs and clinicians.

Cartagenia Bench is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.

For more information, visit www.cartagenia.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of \$4.0 billion in fiscal 2014. The company employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

#

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.